GC GC Holdings
A Game Changer in Global Total Health Care
The GC Group leading the digital healthcare industry
based on its strong pharmaceutical foundation.
more
The GC Group leading the digital healthcare industry
based on its strong pharmaceutical foundation.
Dreaming of a world where humanity no longer must suffer from disease and illnesses, the GC Group is taking large strides as a global leader in the health industry rising above and beyond the scope of a domestic health care company.
With a total of 40 affiliates at home and abroad (25 domestic, 15 overseas), the GC Group delegates the management of the entire Group operations, including strategic direction, new business creation, and portfolio management to the GC Holdings company, while each affiliate takes charge of the manufacturing and sales of special medicine and digital healthcare business.
GC Group is a biotech-based global total healthcare group that encompasses products and services such as disease prevention, diagnosis, treatment, medical devices, and healthcare.
With a total of 40 affiliates at home and abroad (25 domestic, 15 overseas), the GC Group delegates the management of the entire Group operations, including strategic direction, new business creation, and portfolio management to the GC Holdings company, while each affiliate takes charge of the manufacturing and sales of special medicine and digital healthcare business.
GC Group is a biotech-based global total healthcare group that encompasses products and services such as disease prevention, diagnosis, treatment, medical devices, and healthcare.
Shortcut
It was established as a global strategy of GC and produces blood products.
It is equipped with excellent facilities, which received the on-site certification by Ministry of National Health in 1998 and passed the Chinese GMP for the first time from Anhui province.
It is equipped with excellent facilities, which received the on-site certification by Ministry of National Health in 1998 and passed the Chinese GMP for the first time from Anhui province.
The company is achieving its vision of global health by supplying the United States with superior pharmaceutical assets proven by GC Biopharma.
It was established as a strategy to expand the business of GC in South America.
It contributes to sales growth in South America by providing local services necessary for products and products businesses such as blood products, vaccines, and rare disease treatments.
It contributes to sales growth in South America by providing local services necessary for products and products businesses such as blood products, vaccines, and rare disease treatments.
It is a plasma screening company established as a global strategy for blood product development.
It is expanding its scope to general tests and special tests and has obtained international certifications such as CLIA, CAP, and ISO.
It is expanding its scope to general tests and special tests and has obtained international certifications such as CLIA, CAP, and ISO.
It is a subsidiary company of GC Cell and is a representative cell therapy research and sales company in Japan.
In 2015, the company obtained "permission to manufacture specific cell processed products" from MHLW of japan, providing cell therapy products and services.
In 2015, the company obtained "permission to manufacture specific cell processed products" from MHLW of japan, providing cell therapy products and services.
It has systems for clinical trials and systems for tracking and documenting the processing of cell therapy products. It also serves as a hub for human resources development programs in biotechnology.
Curevo is based in Seattle and is currently undergoing clinical trials for the next-generation shingles vaccine. It will become the next-generation vaccine company by promoting global clinical development of innovative preventive vaccines and therapeutic vaccines for infectious diseases.
It is building expertise in vaccine research through collaboration with the global vaccine agency Infectious Disease Research Institute (IDRI).
It is building expertise in vaccine research through collaboration with the global vaccine agency Infectious Disease Research Institute (IDRI).
It is an "NRDO" (No Research Development Only) company that adopts GC Cell's CAR technology and NK cell therapy pipeline without developing its own original technology.
Through the Remote Patient Monitoring (RPM) platform 'Broccoli365', routine data monitoring and CARE programs are provided to patients with chronic diseases.